ERAP modulators

Many antigenic peptides presented by MHC class I molecules are initially created through proteolysis by the proteasome as precursors. The trimming of these precursors to the final epitope is performed in the ER by ERAP-1 and ERAP-2. Genome wide Association Studies have linked ERAP1 and ERAP2 with predisposition to human diseases with autoimmune aetiology such as rheumatic diseases (most notably Ankylosing Spondylitis) and also with cancers and response to cancer immunotherapy. Also, the function of these proteases and their 3D-structure are well documented. While the short term goal of the proposal is the identification of promising leads, the long term goal is the generation of novel pharmacological approaches towards the treatment of ERAP-associated human diseases based on the modulation of antigen processing and adaptive immune response with applications in autoinflammatory diseases and in cancer immunotherapy.

Team

  • Team Leader: Pr Rebecca Deprez-Poulain PhD - PharmD
  • Vasileios Fougiaxis PhD– PostDoc, PharmD
  • Paul Blanchart– PhD student
  • Marcin Piezinski PhD - PostDoc
  • Nour Bou Karroum PhD- Ass. Pr
  • Florence Leroux PhD - PharmD Biochemist
  • Adrien Herledan – Study Eng
  • Morgane Tardy - Study Eng
  • Kim Ly PhD - Study Eng
  • Camille Fauré - Study Eng
  • Paul Carré - Ass Eng

former members : Laetitia Lesire; Ronan Gealageas; Paul Hermant; Keguang Cheng; Omar Castillo; Laura Medve; Pierre Sierocki; Charlotte Tabey; Valentina Barcherini; Tuhina Khan; Milena Petrovic; Ben He; Rodolphe Vatinel; Virgyl Camberlein

Collaborators

  • Pr. van Endert, U1013 INSERM, Hopital Necker. France Cell biology & antigenic presentation
  • Dr. Stratikos, Demokritos Research Center, Athens, Greece. Cell Biology & X-ray.
  • Pr Bouvier, IUC Chicago, USA, Structural biology
  • Pr. Launay, INFINITE INSERM U1286, Lille Regional Hospital, University of Lille. Immunity
  • Dr Fruci, OPBG, Rome, Italy. Immunooncology
  • Dr James, Univ. Southampton, United Kingdom, Immunooncology
  • Dr Roche, Edelris, Lyon. medicinal chemistry
  • CAPSTONE CONSORTIUM

Grants

  • ANR Grant MASTERY 2025-2028
  • LeoPharma fondation Grant 2024-2027
  • ANR Grant ERAPIMM 2020-2023
  • H2020 MSCA ITN CAPSTONE 2021-2025
  • Region Hauts de France STARTAIRR 2022
  • FRM Grant 2019-2021
  • IUF Grant 2015-2020
  • Campus France Hubert-Curien Grant 2013-2014

ANR MASTERY project

The project “MASTERY” Modulation of Antigen ProceSsing for ThERapY  has been granted by ANR for 3 years (Nov 2025- Nov 2028). The below teams collaborate in a project aiming at discovering and developing of  ERAP inhibitors for autoimmune diseases and for immuno-oncology with original approaches.

  • Pr R. Deprez-Poulain (Coordinator, M2SV, INSERM U1177, Institut Pasteur de Lille, University of Lille),
  • Dr D. Roche (EDELRIS, Lyon)

ANR-25-CE18-0658, PRCE.

 

Leo Foundation grant project

  • The team has been awarded a grant (2024-2027) entitled "Inhibitors of ERAP1 or ERAP2 to modulate antigen processing towards new psoriasis treatment".
  • The project will combine structural biology, medicinal chemistry, biochemistry, and cellular biology to optimize current compounds into potent and selective inhibitors targeting ERAP. It will assess their therapeutic potential in purposely designed transgenic mouse models containing human ERAP, as well as in patient cells.
  • The project may define the optimal profile of an ERAP inhibitor as a pharmacological tool, providing a foundation for the exploration of ERAP roles and eventually an ERAP-based oral treatment for psoriasis.

CAPSTONE ETN project

The project CAPSTONE has been granted by EU H2020 MSCA-ITN for 4 years (Jan 2021-Jun 2025).

  • CAPSTONE (Controlling Antigen Processing in Autoimmune diseases and Cancer) PhD project is a multi-disciplinary platform of experts in structural biology, immunology, biochemistry, proteomics, and therapeutics that jointly aim to increase the impact of research into ERAP aminopeptidases in various aspects of human and animal disease.
CAPSTONE website

ANR ERAPIMM project

The project “ERAPIMM” has been granted by ANR for 3 years (Nov 2020- Nov 2023). The below teams collaborate in a project aiming at discovering and developing of  ERAP inhibitors as a new approach to treat autoimmune & auto-inflammatory diseases. In particular, the teams will specifically study applications in Type 1 diabetes, Behcet’s disease and Spondyloarthritis.

  • Pr R. Deprez-Poulain (Coordinator, M2SV, INSERM U1177, Institut Pasteur de Lille, University of Lille),
  • Pr P. van Endert ( INEM, INSERM U1151 –CNRS UMR 8253, University of Paris)
  • Pr D. Launay (INFINITE, INSERM U1286, Lille Regional Hospital, University of Lille)

Publications

2026 

  • Vasconcelos, F., Lima, A. C., Bonani, W., Silva, C. S., Reis, R. L., Motta, A., Migliaresi, C., Martins, A., & Neves, N. M. Microfluidic-assisted electrospinning, an alternative to coaxial, as a controlled dual drug release system to treat inflammatory arthritic diseases. Biomaterials Advances,2022, 134: 112585. 10.1016/j.msec.2021.112585; HAL

2025

  • Leib, J., Waeckel-Énée, E., Fabrega, S., Keelan, N., Senni, A., Mauvais, F. X., Deprez-Poulain, R., Bertocci, B., & van Endert, P. ERAP1-dependent extreme antigen processing efficacy can govern MHC class I expression hierarchy. J. Immunol.,2025 10.1093/jimmun/vkaf013. 
  • He, B., Karroum, N. B., Gealageas, R., Mauvais, F.-X., Warenghem, S., Roignant, M., Kraupner, N., Lam, B. V., Azaroual, N., Ultré, V., Rech, A., Lesire, L., Couturier, C., Leroux, F., van Endert, P., Deprez, B., & Deprez-Poulain, R. Discovery of New Nanomolar Selective IRAP Inhibitors. J. Med. Chem.,2025.10.1021/acs.jmedchem.4c01744. HAL

2024

  • Ponzoni, A., Speca, S., Hartle, M., Gerstenberg, A., Tomezyk, A., Senechal, V., Karnik, S., Dubuquoy, L., Launay, D., Deprez-Poulain, R., Gaudin, M., Ramos, C., & Deprez, B. An untargeted metabolomic study using MALDI-mass spectrometry imaging reveals region-specific biomarkers associated with bowel inflammation. Metabolomics,2024, 21(1): 5. 10.1007/s11306-024-02200-4  OPEN ACCESS
  • Fougiaxis, V., Barcherini, V., Petrovic, M. M., Sierocki, P., Warenghem, S., Leroux, F., Bou Karroum, N., Petit-Cancelier, F., Rodeschini, V., Roche, D., Deprez, B., & Deprez-Poulain, R. First fragment-based screening identifies new chemotypes inhibiting ERAP1-metalloprotease. Eur. J. Med. Chem.,2024, 280: 116926. 10.1016/j.ejmech.2024.116926. OPEN ACCESS  HAL
  • Fougiaxis, V., He, B., Khan, T., Vatinel, R., Koutroumpa, N. M., Afantitis, A., Lesire, L., Sierocki, P., Deprez, B., & Deprez-Poulain, R. ERAP Inhibitors in Autoimmunity and Immuno-Oncology: Medicinal Chemistry Insights. J. Med. Chem.,2024. 10.1021/acs.jmedchem.4c00840. OPEN ACCESS  HAL

2022

  • Camberlein, V., Fleau-Tabey, C., Sierocki, P., Li, L., Gealageas, R., Bosc, D., Guillaume, V., Warenghem, S., Leroux, F., Rosell, M., Cheng, K., Medve, L., Prigent, M., Decanter, M., Piveteau, C., Biela, A., Eveque, M., Dumont, J., Mpakali, A., Giastas, P., Herledan, A., Couturier, C., Haupenthal, J., Lesire, L., Hirsch, A. K., Deprez, B., Stratikos, E., Bouvier, M., & Deprez-Poulain, R. Discovery of the First Selective Nanomolar Inhibitors of Endoplasmic Reticulum Aminopeptidase 2 by Kinetic Target-Guided Synthesis. Angewandte Chemie International Edition,2022,61, 39 , e202203560.10.1002/anie.202203560  HAL

2020

  • Medve, L., Gealageas, R., Lam, B. V., Guillaume, V., Castillo-Aguilera, O., Camberlein, V., Piveteau, C., Rosell, M., Fleau, C., Warenghem, S., Charton, J., Dumont-Ryckembusch, J., Bosc, D., Leroux, F., van Endert, P., Deprez, B., & Deprez-Poulain, R. Modulators of hERAP2 discovered by High-Throughput Screening. Eur. J. Med. Chem.,2020, 211: 113053.10.1016/j.ejmech.2020.113053  HAL

2017

  • Mpakali, A., Giastas, P., Deprez-Poulain, R., Papakyriakou, A., Koumantou, D., Gealageas, R., Tsoukalidou, S., Vourloumis, D., Mavridis, I. M., Stratikos, E., & Saridakis, E. Crystal Structures of ERAP2 Complexed with Inhibitors Reveal Pharmacophore Requirements for Optimizing Inhibitor Potency. ACS Medicinal Chemistry Letters, 2017, 8(3): 333-337.doi:10.1021/acsmedchemlett.6b00505

Conferences

2026

  • Blanchart, P. Design and implementation of kinetic target-guided synthesis for allosteric sites,33rd Young research Fellow Meeting SCT,11h–13th Feb. 2026 

2025

  • Bou Karroum, N. Conception du médicament : Du design rationel à la découverte d'inhibiteurs puissants de l'aminopeptidase contrôlée pas l'insuline (IRAP) - Webinar "Save Your Fridays",Lille, France,27th June 2025
  • Deprez-Poulain, R. First selective nanomolar inhibitors of ERAP2 in autoimmune diseases,XXI National Meeting of the Spanish Society of Medicinal Chemistry Sevilla, Spain,15th-18th Jun. 2025 Invited 
  • Deprez-Poulain, R. Discovery of ERAP2 selective inhibitors,CAPSTONE Open Conference: Targeting Antigen Processing in Autoimmunity and Cancer,Paris, France,31st Mar. 2025 

2024

  • Bou Karroum, N. Discovery of novel and selective IRAP inhibitors,IRAP International Symposium,Prato, Italy ,22nd-25th Sept 2024
  • Deprez-Poulain, R. CAPSTONE-ETN: a European consortium dedicated to antigen processing and presentation.,9th Scientific Meeting of the Institut Pasteur de Lille Lille, France,4th June 2024

2022

  • Deprez-Poulain, R. MHC-I-opathies: Inhibitions des ERAPs comme nouvelle stratégie thérapeutique dans la maladie de Behcet et la chorioretinopathie de Birdshot, Colloque De la Recherche aux traitements dans les maladies rares,Fondation Maladies Rares,Institut Gernez Rieux, lille,17 Nov. 2022 Invited
  • Deprez-Poulain, R. First Selective Nanomolar Inhibitors of ERAP2 for Modulation of the Antigen Presentation,XXVII EFMC International Symposium on Medicinal Chemistry,Nice, France,4-8th september 2022.
  • Deprez-Poulain, R. IDE and ERAP inhibitors discovered by KTGS and their use in therapeutics,GP2A 2022 - 30th Annual Conference,Dublin, IE,24th-26th Aug. 2022 Invited.
  • Sierocki, P. Overcoming peptidic scaffolds' limitations using KTGS : Discovery of the 1st selective and druglike ERAP2 inhibitors,29th SCT Young Research Fellows Meeting,Nantes, France,4-6th July 2022

2021

  • Sierocki, P. Discovery & binding study of hERAP2 modulators identified via HTS,GP2A 2021 - 29th Annual Conference,Virtual conference,25th-27th Aug. 2021
  • Deprez-Poulain, R. Kinetic target-guided synthesis et acides hydroxamiques des outils efficaces pour la drug-discovery ciblant les metalloproteases.,CEISAM, Nantes, France,26th Mar. 2021 Invited.

2020

  • Camberlein, V., Gealageas, R., Tabey-Fleau, C., Warenghem, S., Guillaume, V., Bosc, D., Florence, L., Benoit, d., & deprez-Poulain, R. Discovery of hERAP2 inhibitors by kinetic target-guided synthesis,5th Drug Discovery Day - Conception Synthèse Evaluation et Sélection du principe actif,Lille, France,16th Dec. 2020
  • Deprez-Poulain, R., Antigen presentation and pharmacological modulation of ERAPs for autoimmune diseases, including type 1 diabetes, Live Webinar on Webex Events,16th-17th June 2020 Invited.

2019

  • Deprez-Poulain, R. Validating new metalloproteases targets in drug discovery using small molecules,GDCh-Wissenschaftsforum Chemie,GDCh,Aachen, Germany,15th-18th Sept. 2019 Invited.
  • Deprez-Poulain, R. Kinetic Target-Guided Synthesis as a Tool for Drug-Discovery: Successes, Challenges and Applications to Metalloproteases,2nd Molecules Medicinal Chemistry Symposium,Barcelona, Spain,15th-17th May 2019 Invited.

2018

  • Deprez-Poulain, R. Pharmacological modulation of antigen processing and presentation: new therapeutic approach for cancer and autoimmune diseases,4th Scientific Meeting of the Institut Pasteur de Lille,Marcq en Baroeul, France,18 Jun. 2018 Invited
  • Deprez-Poulain, R. Nouveaux médicaments du cancer et des maladies auto-immunes : dompter le système immunitaire à des fins thérapeutiques,Conférences 5à7 Médicaments,Institut Pasteur de Lille, France,17th Apr. 2018

Communications

2026

  • Blanchart, P., Bou Karroum, N., Piveteau, C., Biela, A., & Deprez-Poulain, R. Design and implementation of kinetic target-guided synthesis for allosteric sites. 33rd Young Research Fellow Meeting SCT, Marseille, FR, 11th–13th Feb.,2026.

2025

  • Blanchart, P., Bou Karroum, N., Piveteau, C., Biela, A., & Deprez-Poulain, R. Design and implementation of kinetic target-guided synthesis for allosteric sites 10th Drug Discovery Day, Lille, FR, 12th Dec.,2025.
  • Bou Karroum, N., He, B., Gealageas, R., Mauvais, F.-X., Warenghem, S., Roignant, M., Kraupner, N., Lam, B. V., Lesire, L., Couturier, C., Leroux, F., Van Endert, P., Deprez, B., & Deprez-Poulain, R. Discovery of novel and selective IRAP inhibitors 32nd Young Research Fellow Meeting SCT, Paris, FR, 26th-28th feb.,2025.
  • Fougiaxis, V., Barcherini, V., Petrovic, M., Sierocki, P., Warenghem, S., Leroux, F., Bou Karroum, N., Petit-Cancelier, F., Rodeschini, V., Roche, D., Deprez, B., & Deprez-Poulain, R. Discovery of novel chemotypes as ERAP1-metalloprotease inhibitors through fragment-based screening 32nd Young Research Fellow Meeting SCT, Paris, FR,26th-28th Feb.,2025.
  • Bou Karroum, N., He, B., Gealageas, R., Mauvais, F.-X., Warenghem, S., Roignant, M., Kraupner, N., Lam, B. V., Lesire, L., Couturier, C., Leroux, F., Van Endert, P., Deprez, B., & Deprez-Poulain, R. Discovery of novel and selective IRAP inhibitors 10th Scientific Meeting of the Institut Pasteur de Lille Lille, FR, 17th Jun.,2025.
  • De Vasconcelos, F., Scaldaferri, V., Gragera, P., Król, K., Lesire, L., Herledan, A., Iatrou, H., Deprez-Poulain, R., & Fruci, D. Efficacy of novel potential ERAP inhibitors to enhance anticancer immunity CAPSTONE Open Conference : Targeting Antigen Processing in Autoimmunity and Cancer, INEM, Paris, France, 31st Mar.,2025.
  • Lesire, L., Herledan, A., Leroux, F., Couturier, C., Deprez, B., & Deprez-Poulain, R. High-throughput screening for discovering bioactive compounds that modulates antigen presentation CAPSTONE Open Conference : Targeting Antigen Processing in Autoimmunity and Cancer, INEM, Paris, France, 31st Mar.,2025.
  • Bou Karroum, N., He, B., Gealageas, R., Mauvais, F.-X., Warenghem, S., Roignant, M., Kraupner, N., Lam, B. V., Lesire, L., Couturier, C., Leroux, F., van Endert, P., Deprez, B., & Deprez-Poulain, R. Discovery of novel and selective IRAP inhibitors CAPSTONE Open Conference : Targeting Antigen Processing in Autoimmunity and Cancer, INEM, Paris, France, 31st Mar.,2025.
  • Fougiaxis, V., Barcherini, V., Petrovic, M., Sierocki, P., Warenghem, S., Leroux, F., Bou Karroum, N., Petit-Cancelier, F., Rodeschini, V., Roche, D., Deprez, B., & Deprez-Poulain, R. Discovery of new chemotypes as erap1-metalloprotease inhibitors through fragment-based screening CAPSTONE Open Conference : Targeting Antigen Processing in Autoimmunity and Cancer, INEM, Paris, France, 31st Mar. ,2025.

2024

  • Fougiaxis, V., Barcherini, V., Petrovic, M., Sierocki, P., Warenghem, S., Leroux, F., Bou Karroum, N., Petit-Cancelier, F., Rodeschini, V., Roche, D., Deprez, B., & Deprez-Poulain, R. Discovery of novel chemotypes as Erap1 metalloprotease inhibitors through fragment-based screening XXVIII EFMC-ISMC, Rome, Italy, 1st-5th Sept.,2024.
  • Fougiaxis, V.; He, B.; Khan, T.; Vatinel, R.; Koutroumpa, N. M.; Afantidis, A.; Lesire, L.; Sierocki, P.; Deprez, B.; Deprez-Poulain, R.; . Erap Inhibitors : A Medicinal Chemistry Dashboard. In EFMC-ISMC 2024 - XXVIII EFMC International Symposium on Medicinal Chemistry, Roma, IT, 1-5th Sept., 2024.
  • Bou Karroum, N., He, B., Gealageas, R., Mauvais, F.-X., Warenghem, S., Roignant, M., Kraupner, N., Lam, B. V., Lesire, L., Couturier, C., Leroux, F., Van Endert, P., Deprez, B., & Deprez-Poulain, R. Discovery of novel and selective IRAP inhibitors EFMC-ISMC 2024 - XXVIII EFMC International Symposium on Medicinal Chemistry, Rome, Italy, 1-5th Sept.,2024.

2023

  • He, B., Warenghem, S., Leroux, F., Vatinel, R., Sierocki, P., Barcherini, V., Kraupner, N., Deprez, B., & Deprez-Poulain, R. Discovery of potent IRAP inhibitors using a combination of docking and SAR 8th Drug Discovery Day, Lille, France, 15th Dec.,2023.
  • He, B., Warenghem, S., Leroux, F., Vatinel, R., Sierocki, P., Barcherini, V., Kraupner, N., Deprez, B., & Deprez-Poulain, R. Design and development of selective carboxylic acid IRAP inhibitor by computer aided rational design 57th International Conference on Medicinal Chemistry, RICT, Drug Discovery and Selection, Lille, France, 5th-7th July,2023.
  • Sierocki, P., Camberlein, V., Tabey-Fleau, C., Gealageas, R., Biela, A., Piveteau, C., Warenghem, S., Dumont, J., Leroux, F., Lesire, L., Deprez, B., & Deprez-Poulain, R. Discovery of the 1st selective ERAP2 modulators able to modulate antigenic presentation in cell, using KTGS 57th International Conference on Medicinal Chemistry, RICT, Drug Discovery and Selection, Lille, France, 5th-7th July,2023.
  • Kraupner, N., Lesire, L., Herledan, A., Warenghem, S., Leroux, F., Deprez, B., Deprez-Poulain, R., & Bosc, D. Crystallography-oriented design of PROTAC® compounds targeting the Insulin Degrading Enzyme (IDE) 57th International Conference on Medicinal Chemistry, RICT, Drug Discovery and Selection, Lille, France, 5th-7th July,2023.
  • Vasileios, F., Sierocki, P., Piveteau, C., Biela, A., Warenghem, S., Leroux, F., Deprez, B., & Deprez-Poulain, R. Design and optimization of KTGS strategy towards M1 metalloprotease hit identification 57th International Conference on Medicinal Chemistry, RICT, Drug Discovery and Selection, Lille, France, 5th-7th July,2023.
  • He, B., Vasileios, F., Sierocki, P., Koutroumpa, N. M., Afantidis, A., Deprez, B., & Deprez-Poulain, R. Potency, selectivity and physicochemical properties of ERAP inhibitors 57th International Conference on Medicinal Chemistry, RICT, Drug Discovery and Selection, Lille, France, 5th-7th July,2023.
  • He, B., Warenghem, S., Leroux, F., Vatinel, R., Sierocki, P., Barcherini, V., Kraupner, N., Deprez, B., & Deprez-Poulain, R. Discovery of potent IRAP inhibitors using a combination of docking and SAR 8th Drug Discovery Day, Lille, France, 15th Dec.,2023.

2022

  • He, B., Fougiaxis, V., Warenghem, S., Leroux, F., Vatinel, R., Sierocki, P., Deprez, B., & Deprez-Poulain, R. Design and development of ERAP1 immunomodulators through combinatorial and innovative medicinal chemistry strategies 29th SCT Young Research Fellows Meeting, Nantes, France, 4-6th July,2022.
  • He, B., Fougiaxis, V., Warenghem, S., Leroux, F., Vatinel, R., Sierocki, P., Deprez, B., & Deprez-Poulain, R. Design and development of ERAP1 immunomodulators through combinatorial and innovative medicinal chemistry strategies. XXVII EFMC International Symposium on Medicinal Chemistry,Nice, France,4-8th september 2022.

2021

  • Vatinel, R., Sierocki, P., Medve, L., Gealageas, R., Guillaume, V., Rosell, M., Warenghem, S., Leroux, F., Piveteau, C., Deprez, B., & Deprez-Poulain, R. Discovery of hERAP2 modulators via high-throughput screening,8th EFMC Young Medicinal Chemists’ Symposium, Virtual conference, 9th-10th Sept.,2021.
  • Camberlein, V., Kraupner, N., Bou Karroum, N., Lipka, E., Deprez-Poulain, R., Deprez, B., & Bosc, D. One-pot procedure for the preparation of 1,5-disubstituted 1,2,3-triazoles by in-situ generation of azides,XXVI EFMC International Symposium on Medicinal Chemistry, Virtual conference, 29th Aug. - 2nd Sept.,2021.
  • Camberlein, V., Sierocki, P., Gealageas, R., Fleau, C., Guillaume, V., Bosc, D., Lesire, L., Warenghem, S., Leroux, F., Deprez, B., & Deprez-Poulain, R. Kinetic target guided synthesis enables the discovery of the first selective nanomolar inhibitors of erap2 for personalized immuno-oncology,XXVI EFMC International Symposium on Medicinal Chemistry, Virtual conference, 29th Aug. - 2nd Sept.,2021.
  • Camberlein, V., Gealageas, R., Fleau, C., Guillaume, V., Bosc, D., Medve, L., Stratikos, E., Warenghem, S., Deprez, B., & Deprez-Poulain, R. First ERAP2 selective inhibitors by kinetic-target guided synthesis to modulate antigen presentation in cancer,56th International Conference on Medicinal Chemistry, Interfacing Chemical Biology and Drug Discovery, Virtual Event, 7th-9th July,2021.
  • Sierocki, P., Medve, L., Fleau, C., Vatinel, R., Khan, T., Gealageas, R., Rosell, M., Guillaume, V., Warenghem, S., Leroux, F., Piveteau, C., Stratikos, E., Deprez, B., & Deprez-Poulain, R. Discovery & binding study of ERAP2 modulators,56th International Conference on Medicinal Chemistry, Interfacing Chemical Biology and Drug Discovery, Virtual Event, 7th-9th July,2021.
  • Sierocki, P., Vatinel, R., Medve, L., Gealageas, R., Guillaume, V., Rosell, M., warenghem, S., Florence, l., Piveteau, C., Deprez-Poulain, R., & Benoit, D. Discovery of hERAP2 modulators via high throughput screening, 28th SCT Young Research Fellows Meeting, Paris, France, 11th-12th Feb.,2021.

2020

  • Tabey-Fleau, C., Camberlein, V., Gealageas, R., Warenghem, S., Guillaume, V., Bosc, D., Benoit, D., & deprez-Poulain, R. Discovery of hERAP 2 inhibitors by Kinetic Target guided synthesis and hit optimization,5th Drug Discovery Day - Conception Synthèse Evaluation et Sélection du principe actif, Lille, France, Dec.,16th Dec. 2020.
  • Vatinel, R., Sierocki, P., Medve, L., Gealageas, R., Guillaume, V., Rosell, M., Warenghem, S., Florence, L., Piveteau, C., Deprez-Poulain, R., & Benoit, D. Discovery of hERAP2 modulation via high-throughput screening approach 5th Drug Discovery Day - Conception Synthèse Evaluation et Sélection du principe actif, Lille, France, 16th Dec.,2020.
  • Tabey-Fleau, C., Camberlein, V., Gealageas, R., Warenghem, S., Guillaume, V., Bosc, D., Benoit, D., & deprez-Poulain, R. Discovery of hERAP 2 inhibitors by Kinetic Target guided synthesis and hit optimization,27th SCT Young Research Fellow Meeting, Caen, France, 29th-31st Janv.,2020.

2019

  • Castillo-Aguilera, O., Rosell, M., Lam, B. V., Warenghem, S., Guillaume, V., Camberlein, V., Bosc, D., Leroux, F., Deprez, B., & Deprez-Poulain, R. Ullman-derived inhibitors of ER-aminopeptidases (ERAP) Drug Discovery Day, Lille, France, 18th jan,2019.
  • Castillo-Aguilera, O., Rosell, M., Lam, B. V., Warenghem, S., Guillaume, V., Camberlein, V., Bosc, D., Leroux, F., Deprez, B., & Deprez-Poulain, R. Ullman-derived inhibitors of ER-aminopeptidases (ERAP) 26th SCT Young Research Fellow Meeting, Paris, France, 20th-22nd Feb.,2019.

2018

  • Lam, B. V., Gealageas, R., Warenghem, S., Guillaume, V., Camberleyn, V., Bosc, D., Leroux, F., Deprez, B., & Deprez-Poulain, R. Ullman-Derived Inhibitors Of Er-Aminopeptidases (Eraps). 54th International Conference on Medicinal Chemistry , Interfacing Chemical Biology and Drug Discovery, Strasbourg, France, 4th-6th July,2018.
  • Lam, B. V., Gealageas, R., Warenghem, S., Guillaume, V., Camberleyn, V., Bosc, D., Leroux, F., Deprez, B., & Deprez-Poulain, R. Ullman-Derived Inhibitors Of Er-Aminopeptidases (Eraps). XXV EFMC International Symposium on Medicinal Chemistry, Ljubljana, Slovenia 2nd-6th Sept.,2018.
2017
  •  Gealageas, R., Dassonneville, S., Dumont-Ryckembusch, J., Bosc, D., Lam, B.-V., Deprez, B., Florence, L., & Deprez-Poulain, R. Discovery of hERAP2 inhibitors by high-throughput screening in 384-format. Antigen processing and presentation, Salamanca, Spain, 28 – 31 May,2017.
  • Gealageas, R., Dassonneville, S., Dumont-Ryckembusch, J., Bosc, D., Lam, B. V., Deprez, B., Leroux, F., & Deprez-Poulain, R. Inhibitors of hERAP2 with unusual Zinc-binding group discovered by High-Throughput Screening in 384-well plate 53rd International Conference on Medicinal Chemistry (RICT), Toulouse, FR, 5th-7th July,2017.
  • Gealageas, R., Dassonneville, S., Dumont-Ryckembusch, J., Bosc, D., Lam, B. V., Hottin, A., Deprez, B., Leroux, F., & Deprez-Poulain, R. Inhibitors of hERAP2 with unusual Zinc-binding group discovered by High-throughput Screening in 384-well plate Drug Discovery Day, Master Seminar, School of Pharmacy, Lille, France, 7th Dec.,2017.

2016

  • Hermant, P., Piveteau, C., Biela, A., Bosc, D., Roignant, M., Deprez, B., & Deprez-Poulain, R. Hit-to-Lead forecasting tools to prevent hydroxamic acids esterasic-metabolism in different species 52nd International Conference on Medicinal Chemistry, RICT 2016, Interfacing Chemical Biology and Drug Discovery, Caen, Normandy, France 6th-8th July, 2016.
  • Hermant, P., Piveteau, C., Biela, A., Bosc, D., Roignant, M., Deprez, B., & Deprez-Poulain, R. Plasma and Microsomal Esterases involvement in the Metabolism of Hydroxamic acids in two species. 2"rd Young Research Fellow Meeting of the SCT, Lille, France, 15th-17th Feb., 2016

2014

  • Zervoudi, E., Hermant, P., Deprez-Poulain, R., & Stratikos, E. Allele-dependent activation of ERAP1 by a small molecule 8th International Workshop on Antigen Processing and Presentation, Philadelphia, USA, 10th-13th Jun, 2014.

Prizes and awards

2022

  • Best Oral Communication to Sierocki, P. (Jul. 2022) Overcoming peptidic scaffolds' limitations using KTGS : Discovery of the 1st selective and druglike ERAP2 inhibitors. 29th SCT Young Research Fellows Meeting, Nantes, France

2020

  • 2020 Michel Delalande Prize of the Academie Nationale de Pharmacie to R. Deprez-Poulain (Dec. 2020).

2019

  • 4th Drug Discovery Day Best Oral Communciation Prize to Camberlein, V. (Dec 2019) Discovery of hERAP2 inhibitors by in situ click chemistry.  Lille, France. 

2015

  • Institut Universitaire de France, Junior Member to Deprez-Poulain, R., 2015-2020.
TOP